Syndax Pharmaceuticals (SNDX)
(Delayed Data from NSDQ)
$21.75 USD
-0.22 (-1.00%)
Updated May 10, 2024 04:00 PM ET
After-Market: $21.77 +0.02 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.75 USD
-0.22 (-1.00%)
Updated May 10, 2024 04:00 PM ET
After-Market: $21.77 +0.02 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Zacks News
Inovio (INO) Q2 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Inovio Pharmaceuticals' (INO) most advanced pipeline candidate, VGX-3100 vaccine's consistent progress might drive the stock in Q2. However, lack of an approved product in portfolio is a dampener.
What's in Store for Puma (PBYI) this Earnings Season?
by Zacks Equity Research
Recent approval of Puma's (PBYI) lead candidate, neratinib, by the FDA might offer a huge boost to the company in Q2, though no sales from the drug will be recorded during the same.
What's in Store for Arena (ARNA) this Earnings Season?
by Zacks Equity Research
Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive performance so far, the company's efforts to improve the drug's performance might drive the stock in Q2.
Will ACADIA (ACAD) Pull Off a Surprise this Earnings Season?
by Zacks Equity Research
ACADIA Pharmaceuticals' (ACAD) Nuplazid is expected to maintain the growth trend, established since its launch, in the second quarter.
Repros (RPRX) Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Lack of revenues in Repros Therapeutics' (RPRX) product portfolio could be a concern. But the company's most advanced pipeline candidates -- enclomiphene and Proellex -- might better its results in Q2.
Can Ligand (LGND) Pull a Surprise This Earnings Season?
by Zacks Equity Research
Milestone payment on Baxdela's approval in the U.S. leveraging Ligand's (LGND) Captisol formulation technology and partnerships with leading healthcare companies, might drive the company in Q2.
GW Pharmaceuticals (GWPH) Q3 Earnings: What Lies in Store?
by Zacks Equity Research
Investors will likely be looking at GW Pharmaceuticals' (GWPH) progress with its anti-epileptic pipeline candidate, Epidiolex in its fiscal third-quarter results.
Can Mallinckrodt (MNK) Deliver a Beat this Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on Mallinckrodt plc's (MNK) progress with its strategic acquisitions and pipeline updates.
What's in the Cards for Adverum (ADVM) this Earnings Season?
by Zacks Equity Research
Investors will be looking at Adverum's (ADVM) updates on progress of its various pipeline candidates.
What's in the Cards for Merrimack (MACK) in Q1 Earnings?
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) is expected to report first-quarter 2017 results around May 1. Last quarter, Merrimack missed bottom line expectations
Intrexon (XON): Will the Stock Pull a Surprise in Q4 Earnings?
by Zacks Equity Research
Intrexon Corporation (XON) is scheduled to report fourth-quarter 2016 results on Mar 1, after the market closes.
Agenus (AGEN): What's Ahead for the Stock in Q4 Earnings?
by Zacks Equity Research
Agenus Inc. (AGEN) is expected to report fourth-quarter 2016 results during this month.
Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) is expected to report fourth-quarter 2016 results next month. The company has a mixed earnings history.
Arena Pharmaceuticals (ARNA) Q4 Earnings: What to Expect?
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) is expected to report fourth-quarter 2016 results next month.
Keryx (KERX) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Keryx Biopharmaceuticals, Inc. (KERX) is expected to report fourth-quarter 2016 results on Mar 1.
ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?
by Zacks Equity Research
ACADIA Pharmaceuticals Inc. (ACAD) is expected to report fourth-quarter 2016 results on Feb 28.
Jazz Pharma (JAZZ) Q4 Earnings: Is a Surprise in Store?
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) is scheduled to report fourth-quarter 2016 results on Feb 28 after the market closes.